Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2020

27.01.2020 | Breast Oncology

Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy

verfasst von: Brianna L. Cohen, MD, Amber L. Collier, MD, Kristin N. Kelly, MD, MPH, Neha Goel, MD, Susan B. Kesmodel, MD, Danny Yakoub, MD, PhD, Mecker Moller, MD, Eli Avisar, MD, Dido Franceschi, MD, Francis I. Macedo, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Occult breast cancer (OBC) is a rare clinical entity. Current surgical management includes axillary lymphadenectomy (ALND) with or without mastectomy. We sought to investigate the role of sentinel lymph node biopsy (SLNB) in patients with OBC treated with neoadjuvant chemotherapy (NAC).

Methods

Patients with clinical T0N+ breast cancer were selected from the National Cancer Data Base (NCDB, 2004–2014) and compared according to axillary surgical approach, SLNB (≤ 4 LNs) or ALND (> 4 LNs). Primary outcome was overall survival (OS), calculated using Kaplan–Meier methods. Secondary outcome was complete pathological response (pCR).

Results

A total of 684 patients with OBC were identified: 470 (68.7%) underwent surgery upfront and 214 (31.3%) received NAC. Of the NAC patients, 34 (15.9%) underwent SLNB and 180 (84.1%) ALND. One hundred and fifty-three (72%) patients received radiotherapy (RT). There was no difference in pCR rates between the ALND and SLNB (34.3% vs 24.5%, respectively p = 0.245). In patients undergoing surgery first, improved OS was observed with ALND compared to SLNB (106.9 vs 85.5 months, p = 0.013); however, no difference in OS was found in patients who received NAC (105.6 vs 111.3 months, p = 0.640). RT improved OS in patients who underwent NAC followed by SLNB (RT, 123 months vs no RT, 64 months, p = 0.034). Of NAC patients who did not undergo RT, ALND had superior survival compared to SLNB (113 vs 64 months, p = 0.013).

Conclusion

This is the first comparative analysis assessing the surgical management of the axilla in patients with OBC who underwent NAC. In this population, there was a decrease in survival in patients who underwent SLNB alone; however, with the addition of RT, there was no difference in OS between SLNB and ALND. SLNB plus RT may be considered as an alternative to ALND in patients with OBC who have a good response to NAC.
Literatur
1.
Zurück zum Zitat Baron PL, Moore M, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.CrossRef Baron PL, Moore M, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125(2):210–4.CrossRef
2.
Zurück zum Zitat Yang H, Li L, Zhang M, et al. Application of neoadjuvant chemotherapy in occult breast cancer: five case reports. Medicine (Baltimore). 2017;96(40):e8200.CrossRef Yang H, Li L, Zhang M, et al. Application of neoadjuvant chemotherapy in occult breast cancer: five case reports. Medicine (Baltimore). 2017;96(40):e8200.CrossRef
3.
Zurück zum Zitat Macedo FI, Eid J, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23(6):1838–44.CrossRef Macedo FI, Eid J, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical management for occult breast carcinoma: a meta-analysis. Ann Surg Oncol. 2016;23(6):1838–44.CrossRef
4.
Zurück zum Zitat Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol. 2017;24(10):2907–14.CrossRef Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing management and outcome in patients with occult breast cancer with axillary lymph node involvement: analysis of the National Cancer Database. Ann Surg Oncol. 2017;24(10):2907–14.CrossRef
5.
Zurück zum Zitat Olson JA Jr, Morris E, Van See KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.CrossRef Olson JA Jr, Morris E, Van See KJ, Linehan DC, Borgen PI. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7(6):411–5.CrossRef
6.
Zurück zum Zitat National Comprehensive Cancer Network. NCCN Guidelines Version 1. Invasive Breast Cancer. 2018 [cited 2019 March 29]. National Comprehensive Cancer Network. NCCN Guidelines Version 1. Invasive Breast Cancer. 2018 [cited 2019 March 29].
7.
Zurück zum Zitat Walker GV, Smith G, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.CrossRef Walker GV, Smith G, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116(17):4000–6.CrossRef
8.
Zurück zum Zitat Miyoshi T, Shiobara M, Watsuki K, et al. Four cases of occult breast cancer treated with breast conserving therapy after neoadjuvant chemotherapy. Gan Kagaku Ryoho. 2017;44(12):1149–51. Miyoshi T, Shiobara M, Watsuki K, et al. Four cases of occult breast cancer treated with breast conserving therapy after neoadjuvant chemotherapy. Gan Kagaku Ryoho. 2017;44(12):1149–51.
9.
Zurück zum Zitat Rueth NM, Black D, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22(1):90–5.CrossRef Rueth NM, Black D, Limmer AR, et al. Breast conservation in the setting of contemporary multimodality treatment provides excellent outcomes for patients with occult primary breast cancer. Ann Surg Oncol. 2015;22(1):90–5.CrossRef
10.
Zurück zum Zitat Wu SG, Zhang W, Li FY, et al. Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis. J Cancer. 2017;8(18):3849–55.CrossRef Wu SG, Zhang W, Li FY, et al. Comparable survival between additional radiotherapy and local surgery in occult breast cancer after axillary lymph node dissection: a population-based analysis. J Cancer. 2017;8(18):3849–55.CrossRef
11.
Zurück zum Zitat Bilimoria KY, Stewart A, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRef Bilimoria KY, Stewart A, Winchester DP, et al. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol. 2008;15(3):683–90.CrossRef
12.
Zurück zum Zitat McCartan DP, Zabor E, Morrow M, Van Zee KJ, El-Tamer MB. Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol. 2017;24:3141–47.CrossRef McCartan DP, Zabor E, Morrow M, Van Zee KJ, El-Tamer MB. Oncologic outcomes after treatment for MRI occult breast cancer (pT0N+). Ann Surg Oncol. 2017;24:3141–47.CrossRef
13.
Zurück zum Zitat Vlastos G, Jean M, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8(5):425–31.CrossRef Vlastos G, Jean M, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8(5):425–31.CrossRef
14.
Zurück zum Zitat Sohn G, Son B, Lee SJ, et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol. 2014;110(3):270–4.CrossRef Sohn G, Son B, Lee SJ, et al. Treatment and survival of patients with occult breast cancer with axillary lymph node metastasis: a nationwide retrospective study. J Surg Oncol. 2014;110(3):270–4.CrossRef
15.
Zurück zum Zitat Khandelwal AK, Garguilo G. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.CrossRef Khandelwal AK, Garguilo G. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. J Am Surg. 2005;190:609–13.CrossRef
16.
Zurück zum Zitat Fisher B, Brown A, Mamounas E, et al. Effect of properative chemotheray on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.CrossRef Fisher B, Brown A, Mamounas E, et al. Effect of properative chemotheray on local regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483–93.CrossRef
17.
Zurück zum Zitat Chehade HEH, Headon H, Tokhy OE, et al. Is sentinal lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969–81.CrossRef Chehade HEH, Headon H, Tokhy OE, et al. Is sentinal lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis? An updated meta-analysis involving 3,398 patients. Am J Surg. 2016;212(5):969–81.CrossRef
18.
Zurück zum Zitat Boughey JC, Suman V, Mittendorf EA, et al. Sentinal lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455–61.CrossRef Boughey JC, Suman V, Mittendorf EA, et al. Sentinal lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer the ACOSOG Z1071 (Alliance) Clinical Trial. JAMA. 2013;310(14):1455–61.CrossRef
19.
Zurück zum Zitat Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRef Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–18.CrossRef
20.
Zurück zum Zitat Laughlin BS, Ehsani S, Chalasani P, Gonzalez V. Oncologic outcomes with neoadjuvant chemotherapy and breast conservation for MRI occult breast cancer. Arch Breast Cancer. 2018;5(3):137–42. Laughlin BS, Ehsani S, Chalasani P, Gonzalez V. Oncologic outcomes with neoadjuvant chemotherapy and breast conservation for MRI occult breast cancer. Arch Breast Cancer. 2018;5(3):137–42.
21.
Zurück zum Zitat Kapoor NS, Sim M, Lin J, et al. Long-term outcome of patients managed with sentinal lymph node biopsy alone for node-negative-invasive breast cancer. Arch Surg. 2012;147(11):1047–52.CrossRef Kapoor NS, Sim M, Lin J, et al. Long-term outcome of patients managed with sentinal lymph node biopsy alone for node-negative-invasive breast cancer. Arch Surg. 2012;147(11):1047–52.CrossRef
22.
Zurück zum Zitat Gherghe M, Bordea C, Blidaru A. Sentinal lymph node biopsy vs. axillary lymph node dissection in the current surgical treatment of early stage breast cancer. J Med Life. 2015;8(2):176–80.PubMedPubMedCentral Gherghe M, Bordea C, Blidaru A. Sentinal lymph node biopsy vs. axillary lymph node dissection in the current surgical treatment of early stage breast cancer. J Med Life. 2015;8(2):176–80.PubMedPubMedCentral
23.
Zurück zum Zitat Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRef Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349(6):546–53.CrossRef
24.
Zurück zum Zitat Boileau J-F, Poirier B, Basik M, Holloway CMB, et al. Sentinal node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.CrossRef Boileau J-F, Poirier B, Basik M, Holloway CMB, et al. Sentinal node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33:258–64.CrossRef
25.
Zurück zum Zitat Mamtani A, Barrio A, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastasis? Results of a prospective study. Ann Surg Oncol. 2016;23:3467–74.CrossRef Mamtani A, Barrio A, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastasis? Results of a prospective study. Ann Surg Oncol. 2016;23:3467–74.CrossRef
26.
Zurück zum Zitat Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy. A review. JAMA Oncol. 2017;3(4):549–55.CrossRef Pilewskie M, Morrow M. Axillary nodal management following neoadjuvant chemotherapy. A review. JAMA Oncol. 2017;3(4):549–55.CrossRef
27.
Zurück zum Zitat Johnson HM, Irish W, Vohra NA, Wong JH. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): A population analysis. Breast Cancer Res Treat. 2019;177:155–64.CrossRef Johnson HM, Irish W, Vohra NA, Wong JH. The effect of local therapy on breast cancer-specific mortality of women with occult breast cancer and advanced nodal disease (N2/N3): A population analysis. Breast Cancer Res Treat. 2019;177:155–64.CrossRef
28.
Zurück zum Zitat Kemeny MM, Rivera D, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.CrossRef Kemeny MM, Rivera D, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152(1):43–7.CrossRef
29.
Zurück zum Zitat Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet Oncol. 2011;378(9804):1707–16.CrossRef Early Breast Cancer Trialists’ Collaborative Group. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet Oncol. 2011;378(9804):1707–16.CrossRef
30.
Zurück zum Zitat McGale P, Taylor C, Correa C, et al. Effect of radiotheray after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta analysis of individual patient data for 8135 women in 22 randomized trials. Lancet Oncol. 2014;383(9935):2127–35.CrossRef McGale P, Taylor C, Correa C, et al. Effect of radiotheray after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta analysis of individual patient data for 8135 women in 22 randomized trials. Lancet Oncol. 2014;383(9935):2127–35.CrossRef
Metadaten
Titel
Surgical Management of the Axilla in Patients with Occult Breast Cancer (cT0 N+) After Neoadjuvant Chemotherapy
verfasst von
Brianna L. Cohen, MD
Amber L. Collier, MD
Kristin N. Kelly, MD, MPH
Neha Goel, MD
Susan B. Kesmodel, MD
Danny Yakoub, MD, PhD
Mecker Moller, MD
Eli Avisar, MD
Dido Franceschi, MD
Francis I. Macedo, MD
Publikationsdatum
27.01.2020
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2020
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-020-08227-w

Weitere Artikel der Ausgabe 6/2020

Annals of Surgical Oncology 6/2020 Zur Ausgabe

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.